OptimizeRx’s Karina Castagna Named One of the 2023 PM360 ELITE 100
Advancing digital access at point-of-care is Karina Castagna’s key focus and her efforts in this area help provide greater access to life-saving medications for patients. She partners with pharma and their patient support Hub partners to digitize processes at the point of care to bring more awareness to access pathways and make therapies easier for doctors to prescribe and patients to access. Karina believes every life sciences company must have digital as a key pillar in its marketing and access strategy for point-of-care and point-of-prescribe to better serve both patients and providers.
Karina views her role from a patient-centric perspective. Digital platforms allow her and her team to solve providers' challenges in helping patients access much-needed life-altering specialty medications. She helps industry utilize technology that connects the ecosystem from the manufacturer, pharmacy, Hub, and payer to bring therapies to patients.
The PM360 ELITE Awards were established in 2015 to recognize individuals and teams who have made a significant impact on the life sciences and healthcare industries throughout their careers. More than 500 submissions were received, and nominees were evaluated and selected by the PM360 editorial staff based on their accomplishments; testimonials from their bosses, clients, and colleagues; and supporting evidence that reflects the impact of their efforts. A total of 100 winners were selected across 19 categories, including Creative Directors, Data Miners, Digital Crusaders, Disrupters, Entrepreneurs, Environmental Champions, Launch Experts, Leaders of the Future, Marketing Teams, Master Educators, Mentors, Patient Advocates, Philanthropic Heroes, PR Gurus, Sales MVPs, Strategists, Talent Acquisition Leaders, Tech-know Geeks, and Transformational Leaders.
“The life sciences and healthcare at large are constantly evolving industries that are always in search of better ways to care for and communicate with patients, and that change isn’t possible without people like this year’s ELITE 100,” says
PM360 is the premier, must-read magazine for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated healthcare environment.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans, and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended
Andy D’Silva, SVP Corporate Finance
Media Relations Contact
Investor Relations Contact
Source: OptimizeRx Corporation